by Catherine Lai, Vishal Ranpura, Colin Wu, Matthew J. Olnes, Ankur R

Slides:

Advertisements

Similar presentations

Hematology The Study of Blood Blood contains cells, proteins, and sugars Red blood cells transport oxygen- erythrocytes White blood cells are part of the.

Advertisements

High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass by Grace M. Lee, Ian J. Welsby,

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.

A Randomized Phase 3 Study of Peripheral Blood Progenitor Cell Mobilization With Stem Cell Factor and Filgrastim in High-Risk Breast Cancer Patients by.

1 Oliva EN et al Proc ASH 2015;Abstract 91.

Myelodysplastic syndrome(MDS)

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.

How I treat elderly patients with myeloma

An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim.

Skovseth et al. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood.

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Fusion genes in cord blood

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Increased Risk of Cervical Dysplasia in Long-Term Survivors of Allogeneic Stem Cell Transplantation—Implications for Screening and HPV Vaccination Bipin.

Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

by Jon E. Arnason, Federico Campigotto, Donna Neuberg, and James B

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is.

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes by Raphael Itzykson, Simon Crouch, Erica Travaglino, Alex Smith,

by John J. Strouse, Megan E. Reller, David G

Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

by John Anastasi, Rizwan Moinuddin, and Christopher Daugherty

Activity of eltrombopag in severe aplastic anemia

Immunotherapy for acute lymphoblastic leukemia: from famine to feast

Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes by Abdullah Mahmood Ali, Yumin Huang,

Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma by Young Ae Kim, Ja Min Byun, Keeho Park, Gi Hwan Bae, Dukhyoung.

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,

by Seth J. Rotz, Nathan Luebbering, Bradley P

by Alex Aleshin, and Peter L. Greenberg

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

Biological impact of α genes, β haplotypes, and G6PD activity in sickle cell anemia at baseline and with hydroxyurea by Françoise Bernaudin, Cécile Arnaud,

Retrospective analysis of capillary hemoglobin recovery in nearly 1 200 000 blood donor returns by Pia Niittymäki, Mikko Arvas, Antti Larjo, Pirkko Mattila,

by J. Michael Soucie, Paul E. Monahan, Roshni Kulkarni, Barbara A

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia Xin Zhao, Xingmin Feng, Zhijie Wu, Thomas Winkler, Ronan.

by Geling Li, Emily Waite, and Julie Wolfson

by Kaiwen Chen, Matthew P. Cheng, Sarah P

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Volume 2(Supplement 1):1-3

Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

by Mieke Aldenhoven, Brigitte T. A. van den Broek, Robert F

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study by Marius Flasinski, Kira Scheibke, Martin Zimmermann,

Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis by Samuel Yamshon,

Differences in Blood Transfusion Trends Between US and UK Centers

(A) Absolute and (B) change from baseline in 6 min walk distance over time for all patients and by Down syndrome status. (A) Absolute and (B) change from.

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma by Tilmann Bochtler, Maximilian Merz,

Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry by Donald M. Arnold, Ishac Nazy, Rumi.

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia by Benjamin L. Lampson, Haesook T. Kim, Matthew.

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Volume 2(Supplement 1):39-41

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

Trends in the use of head CT and advanced imaging in patients treated with IV thrombolysis from 2008 to Trends in the use of head CT and advanced.

Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease by Joshua J. Field, Elaine Majerus, Victor.

Impact of age on clinical risk scores in follicular lymphoma

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia by Amy K. Keating, Jurgen Langenhorst, John.

Balancing bleeding in brain metastases

Volume 2(Supplement 1):4-7

Presentation transcript:

Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab by Catherine Lai, Vishal Ranpura, Colin Wu, Matthew J. Olnes, Ankur R. Parikh, Aarthi Shenoy, Julie Thompson, Barbara Weinstein, Phillip Scheinberg, A. John Barrett, Ronan Desmond, Neal S. Young, and Christopher S. Hourigan BloodAdv Volume 3(7):980-983 April 9, 2019 ©2019 by American Society of Hematology

Duration of response and time to best response in all patients treated with alemtuzumab. Catherine Lai et al. Blood Adv 2019;3:980-983 ©2019 by American Society of Hematology

Characteristics of patients completing the study. Characteristics of patients completing the study. (A) Characteristics of 9 patients who completed the study and were alive at last follow-up. (B) Trend of median hemoglobin (Hb), ANC, and platelets over time (months) in patients who completed the study. Individual patient changes in hemoglobin, ANC, and platelets from baseline compared with end of study. Red + green, baseline; blue, increase from baseline; green, decrease from baseline. Hypo, hypocellular MDS; Int, intermediate; IPSS-R, revised IPSS; plts, platelets; T dep, T-cell depletion; UPI, unique patient identifier. Catherine Lai et al. Blood Adv 2019;3:980-983 ©2019 by American Society of Hematology